Heparin Calcium

• CAT Number: I028694
• CAS Number: 37270-89-6
• Molecular Formula: C26H42CaN2O37S52+
• Molecular Weight: 1174.98
• Purity: 98%
• Synonyms: Calcium heparin; Ca heparin; Nadroparin calcium; Heparin-calcium; Heparin Ca; Ca-heparin; Heparin-Ca; Heparin calcium salt
• Target: Autophagy
• Solubility: To be determined
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: 6-((5-acetamido-4,6-dihydroxy-2-((sulfooxy)methyl)tetrahydro-2H-pyran-3-yl)oxy)-3-((5-((6-carboxy-4,5-dihydroxy-3-(sulfooxy)tetrahydro-2H-pyran-2-yl)oxy)-6-(hydroxymethyl)-3-(sulfoamino)-4-(sulfooxy)tetrahydro-2H-pyran-2-yl)oxy)-4-hydroxy-5-(sulfooxy)tetrahydro-2H-pyran-2-carboxylic acid, calcium salt
• InChI: InChI=1S/C26H42N2O37S5.Ca/c1-4(30)27-7-9(31)13(6(56-23(7)39)3-55-67(43,44)45)58-26-19(65-70(52,53)54)12(34)16(20(62-26)22(37)38)60-24-8(28-66(40,41)42)15(63-68(46,47)48)14(5(2-29)57-24)59-25-18(64-69(49,50)51)11(33)10(32)17(61-25)21(35)36;/h5-20,23-26,28-29,31-34,39H,2-3H2,1H3,(H,27,30)(H,35,36)(H,37,38)(H,40,41,42)(H,43,44,45)(H,46,47,48)(H,49,50,51)(H,52,53,54);/q;+2
• InChIKey: DAKFRBXJUKNNMQ-UHFFFAOYSA-N
• SMILES: CC(NC1C(O)OC(COS(=O)(O)=O)C(OC2OC(C(OC3OC(CO)C(OC4OC(C(O)C(O)C4OS(=O)(O)=O)C(O)=O)C(OS(=O)(O)=O)C3NS(=O)(O)=O)C(O)C2OS(=O)(O)=O)C(O)=O)C1O)=O.[Ca+2]

Heparin calcium (Cat No.:I028694) is also called heparin and heparin calcium. Heparin calcium injection is a new form of heparin sodium for subcutaneous injection. Heparin calcium can avoid the disturbance of electrolyte balance in blood caused by the process of transforming sodium salt into calcium salt. Recent studies have found that heparin calcium has many non anticoagulant pharmacological effects, such as blood lipid regulation, anti-inflammatory, anti complement, anti allergy, immune regulation, etc.

Reference

1: Zhang Q, Tang X, Shen J. The efficacy and safety of low-molecular-weight heparin calcium combined with Xueshuantong injections in the treatment of elderly acute deep venous thrombosis patients. Am J Transl Res. 2021 Apr 15;13(4):3120-3128. PMID: 34017480; PMCID: PMC8129321.
2: Yagi T, Nakamura H, Wakamatsu T, Imura Y, Tamiya H, Sabe H, Yamashita K, Watanabe M, Takenaka S. Primary breast angiosarcoma with disseminated intravascular coagulation is successfully treated with self-subcutaneous unfractionated heparin calcium injection: A case report. Mol Clin Oncol. 2021 May;14(5):104. doi: 10.3892/mco.2021.2266. Epub 2021 Mar 17. PMID: 33815793; PMCID: PMC8010513.
3: He J, He L, Lu F, Geng B, Xia Y. Low-molecular-weight heparin calcium attenuates the tourniquet-induced ischemia-reperfusion injury in rats. Injury. 2021 Mar 5:S0020-1383(21)00221-7. doi: 10.1016/j.injury.2021.03.006. Epub ahead of print. PMID: 33726921.
4: Osché M, Gusdorf L, Cribier B, Scrivener JN. Pustulose exanthématique aiguë localisée après injections d’héparine calcique [Acute localized exanthematous pustulosis following heparin calcium injections]. Ann Dermatol Venereol. 2020 Mar;147(3):207-211. French. doi: 10.1016/j.annder.2019.09.607. Epub 2020 Feb 3. PMID: 32029300.
5: Kadota H, Imaizumi A, Ishida K, Sashida Y. Successful local use of heparin calcium for congested fingertip replants. Arch Plast Surg. 2020 Jan;47(1):54-61. doi: 10.5999/aps.2019.00815. Epub 2020 Jan 15. PMID: 31964124; PMCID: PMC6976745.
6: Wei N, Qi Y, Yang H, Guo L. Clinical observation of the efficacy of low- molecular-weight heparin calcium in prophylaxis of the deep venous thrombosis following the gynecological tumor surgery. Pak J Pharm Sci. 2018 Nov;31(6(Special)):2835-2839. PMID: 30630795.
7: Tong CX, Xing XF, Qiao SH, Liu L, Shan L. [Effect of Low Molecular Weight Heparin Calcium Combined Compound Danshen Injection on Perinatal Outcomes of Nephrotic Syndrome Patients with Early Onset Severe Pre-eclampsia]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2015 Aug;35(8):957-61. Chinese. PMID: 26485910.
8: Tian M, Liu C. Heparin calcium treated Henoch-Schönlein purpura nephritis in children through inhibiting hyperfibrinolysis. Ren Fail. 2015 Aug;37(7):1100-4. doi: 10.3109/0886022X.2015.1061668. Epub 2015 Jul 2. PMID: 26133741.
9: Suzuki T, Ishii-Watabe A, Hashii N, Nakagawa Y, Takahashi T, Ebisawa A, Nishi S, Fujita N, Bando A, Sekimoto Y, Miyata K, Endo T, Otsu T, Sugimoto S, Kondou T, Fujita Y, Miyanaga N, Mashimo M, Shimada N, Yoden H, Shimamura H, Kurata Y, Koyama S, Kawasaki N. The establishment and validation of efficient assays for anti-IIa and anti-Xa activities of heparin sodium and heparin calcium. Biologicals. 2013 Nov;41(6):415-23. doi: 10.1016/j.biologicals.2013.09.003. Epub 2013 Oct 4. PMID: 24095600.
10: Sun Q, Peng DF, Zheng JF. [Clinical observation of the low molecular weight heparin calcium combined with Yinxing Damo injection on the prevention of deep venous thrombosis after the operation of intertrochanteric fracture]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2011 Nov;31(11):1463-5. Chinese. PMID: 22303704.
11: Liu Q, Chang Y. [Clinical observation of lower extremity deep venous hrombosis (DVT) postoperative fracture treated by Maixuekang capsule and low molecular heparin calcium (Subilin)]. Zhongguo Zhong Yao Za Zhi. 2011 Apr;36(7):945-8. Chinese. PMID: 21761740.
12: Hashii N, Kawasaki N, Itoh S, Qin Y, Fujita N, Hattori T, Miyata K, Bando A, Sekimoto Y, Hama T, Kashimura M, Tatsumi M, Mabuchi K, Namekawa H, Sakai T, Hirose M, Dobashi S, Shimahashi H, Koyama S, Herr SO, Kawai K, Yoden H, Yamaguchi T. Heparin identification test and purity test for OSCS in heparin sodium and heparin calcium by weak anion-exchange high-performance liquid chromatography. Biologicals. 2010 Sep;38(5):539-43. doi: 10.1016/j.biologicals.2010.04.002. Epub 2010 May 7. PMID: 20452241.
13: Miyahara S, Yasu T, Yamada Y, Kobayashi N, Saito M, Momomura S. Subcutaneous injection of heparin calcium controls chronic disseminated intravascular coagulation associated with inoperable dissecting aortic aneurysm in an outpatient clinic. Intern Med. 2007;46(11):727-32. doi: 10.2169/internalmedicine.46.6155. Epub 2007 Jun 1. PMID: 17541224.
14: Ji H, Li SP, Cheng X, Cheng HR, Ng TB, Li P, Li NS. Antithrombotic effects of low-molecular-weight heparin calcium (LMWH-Ca) in experimental models. Gen Pharmacol. 1999 Aug;33(2):207-11. doi: 10.1016/s0306-3623(98)00276-6. PMID: 10461860.
15: Cavezzi A, Ragazzi G, Lonardi R, Tuscano G. Ematoma del muscolo retto addominale quale complicanza della terapia anticoagulante con eparina calcica s.c [Hematoma of the rectus abdominis as a complication of anticoagulant therapy with subcutaneously administered heparin calcium]. Minerva Cardioangiol. 1997 Jun;45(6):273-7. Italian. PMID: 9432568.
16: Cina G, Vernich M, Campisi C, Cascone C, Ofria F, Leopardi N, Maniscalco G, Moricca N, Ceccarelli V, Paolicelli D, Carbone D. Training fisico ed eparina calcica a basse dosi in pazienti affetti da arteriopatia obliterante cronica degli arti inferiori con claudicatio intermittens [Physical training and low- dose heparin-calcium in patients suffering from chronic obliterating arteriopathy of the lower limbs with intermittent claudication]. Minerva Cardioangiol. 1996 Apr;44(4):179-85. Italian. PMID: 8767599.
17: Koch P, Hindi S, Landwehr D. Delayed allergic skin reactions due to subcutaneous heparin-calcium, enoxaparin-sodium, pentosan polysulfate and acute skin lesions from systemic sodium-heparin. Contact Dermatitis. 1996 Feb;34(2):156-8. doi: 10.1111/j.1600-0536.1996.tb02162.x. PMID: 8681559.
18: Casoni P, Dalla Valle R. Neuropatia femorale da ematoma spontaneo del muscolo ileo-psoas in corso di terapia con eparina calcica [Femoral neuropathy due to a spontaneous hematoma of the iliopsoas muscle during therapy with heparin-calcium]. Acta Biomed Ateneo Parmense. 1994;65(5-6):289-96. Italian. PMID: 8592921.
19: Fernandez C, Proto C, Schiassi M, Scotti A. Fattibilità e tollerabilità di un trattamento prolungato con basse dosi di eparina calcica per via sottocutanea in pazienti infartuati. Studio clinico multicentrico [The feasibility and tolerability of prolonged treatment with low doses of heparin-calcium administered subcutaneously in infarct patients. A multicenter clinical study]. Recenti Prog Med. 1993 Dec;84(12):834-42. Italian. PMID: 8108597.
20: de los Santos-Sastre S. Profilaxis de la enfermedad tromboembólica en pacientes médicos: heparina cálcica o heparina de bajo peso molecular? [The prevention of thromboembolic disease in medical patients: heparin-calcium or low-molecular-weight heparin?]. An Med Interna. 1993 Sep;10(9):465-6. Spanish. PMID: 8218806.